• Novo Nordisk plans to cut U.S. list prices for Ozempic, Wegovy, and Rybelsus by up to 50% effective January 1, 2027.
  • Wegovy's price will drop to $675 per month from approximately $1,350, while Ozempic sees a 34% reduction to the same price point.
  • The move aims to address affordability and access issues amid ongoing shortages and intense competition in the GLP-1 drug market.

In a significant shift for the pharmaceutical industry, Novo Nordisk announced plans to dramatically reduce U.S. list prices for its blockbuster weight-loss and diabetes drugs. Starting January 1, 2027, both Ozempic and Wegovy will list for $675 a month—a 50% cut for the anti-obesity therapy Wegovy and a 34% reduction for diabetes treatment Ozempic. The price adjustments will also apply to pill versions including Rybelsus, according to people familiar with the matter.

Novo Nordisk, the Denmark-based pharmaceutical giant formed in 1989 from the merger of insulin pioneers, has seen explosive growth driven by demand for its GLP-1 agonists. With 2023 revenues hitting 232 billion Danish kroner (approximately $34.4 billion USD), the company employs over 69,000 people globally. The planned price cuts come as the market for obesity and diabetes treatments faces persistent shortages, particularly for Wegovy and Ozempic, which compete directly with Eli Lilly's Zepbound.

"This pricing strategy reflects our commitment to improving patient access while maintaining sustainable growth," a company spokesperson said in a statement, though executives declined to comment further on the financial implications. Efforts to reach Eli Lilly for reaction were unsuccessful as of press time.

The reductions target the U.S. market specifically, where list prices have sparked ongoing debates about affordability and equity in healthcare. While the cuts won't take effect until 2027, they signal a strategic pivot as Novo Nordisk scales production to meet overwhelming demand. The company has been investing heavily in internal research and development, ranking high in recent pharmaceutical innovation indexes for its weight-loss drug pipeline.

Market analysts note that the move could pressure competitors to follow suit, potentially reshaping pricing dynamics across the obesity and diabetes treatment landscape. "List price reductions of this magnitude are rare in pharmaceuticals, especially for products with such strong demand," one industry observer commented anonymously. "It suggests Novo is betting on volume growth to offset the lower per-unit revenue."

Short-term implications include potential relief for patients facing high out-of-pocket costs and insurers grappling with coverage decisions. The longer-term outlook remains focused on Novo Nordisk's ability to sustain its leadership position through continued innovation in chronic disease treatments, including ongoing Phase II/III trials for next-generation therapies.

Correction: An earlier version of this article misstated the percentage reduction for Ozempic; it is 34%, not 50%. The price for both drugs will be $675 monthly.